Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 31, 2025	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2024	Jun. 15, 2024
Fair Value, Option, Quantitative Disclosures [Line Items]
Unrealized gain (loss) on investment in equity securities		$ (14,862)		$ 60,704
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Payments for prior acquisition		85,000
Business combination contingent consideration liability		0			$ 0
Progenics | Net Sales Targets for Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		70,000
Progenics | 1095 Commercialization [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		5,000
Progenics | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		$ 10,000
Radiopharm Theranostics Limited
Fair Value, Option, Quantitative Disclosures [Line Items]
Share price (in dollars per share)	$ 0.04	$ 0.02	$ 0.03
Unrealized gain (loss) on investment in equity securities		$ (2,500)
Equity investment, shares (in shares)	133,333,333	282,958,513	149,625,180		149,625,180
Number of shares acquired, equity method investment (in shares)	133,333,333
Payments to acquire equity method investments	$ 5,000		$ 5,000
Equity method investments, fair value disclosure		$ 4,800
Perspective Therapeutics, Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Shares owned (in shares)		11,677,339				11,677,339
Investment owned, fair value		$ 24,900
Share price (in dollars per share)		$ 2.13
Unrealized gain (loss) on investment in equity securities		$ 12,400